List of Therapeutic Companies in Brazil - 3

A Belcher é uma empresa farmacêutica focada na fabricação e distribuição de produtos destinados à saúde humana.

A Bionovis é uma empresa de biotecnologia farmacêutica 100% brasileira com a missão de pesquisar, desenvolver, fabricar e comercializar biofármacos complexos e de alta qualidade para melhorar a vida dos pacientes. Inserida em um ambiente biofarmacêutico global promissor, a Bionovis inova como pioneira na produção de medicamentos biológicos de alta complexidade no Brasil. Com uma equipa de renome, parcerias globais com líderes da indústria e colaborações com as principais instituições públicas nacionais, estamos a estabelecer a tecnologia completa para a produção de uma variedade de anticorpos monoclonais e proteínas terapêuticas. Recursos humanos altamente qualificados, uma infraestrutura de classe mundial e a implementação de know-how de ponta no desenvolvimento e fabricação de medicamentos biológicos complexos são os pilares para a construção de um pipeline composto por biossimilares, biobetters e biofármacos inovadores. **** Bionovis is a 100% Brazilian pharmaceutical biotechnology company with a mission to research, develop, manufacture and market high-quality complex biopharmaceuticals to improve the lives of patients. Set in a promising global biopharmaceutical environment, Bionovis innovates as a pioneer in the production of highly complex biological medicines in Brazil. With a reputable team, global partnerships with industry leaders and collaborations with leading national public institutions, we are establishing the complete technology for the production of a variety of monoclonal antibodies and therapeutic proteins. Highly qualified human resources, a world-class infrastructure and the implementation of state of the art know-how in the development and manufacturing of complex biological drugs are the pillars for the construction of a pipeline composed of biosimilars, biobetters and innovative biopharmaceuticals.

Originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants and microorganisms) into novel therapies, Nintx (Next Innovative Therapeutics) believes plant-based natural products bear huge potential to serve as a superb platform to modulate human biological targets and the microbiome concomitantly, affording therapies for multifactorial diseases (multi-target therapies). Nintx was founded by two experienced PhD scientists, Dr. Miller Freitas (CEO) and Dr. Cristiano Guimarães (CSO), who are the main executives of the company, and Mr. Stephani Saverio, MBA, a healthcare veteran who has been acting as a Non-Executive Board Member for the startup. Nintx is a startup with innovation as core business, right at the center of the strategy, heavily based on advanced technologies, coupled with the Brazilian biodiversity, the most biologically diverse in the world, to develop the next generation of therapies. Some of Nintx's proprietary technologies include xGIbiomics®, which closely emulates the human gastrointestinal digestive system and microbiome, and GAIApath®, an artificial intelligence and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome concomitantly. Nintx's cutting-edge technologies and concepts will be key in the future development of multi-target therapies.